Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 20 years and older in Japan~* Histologically documented metastatic or surgically unresectable urothelial carcinoma; may include primary site from urethra, ureters, upper tract, renal pelvis, and bladder.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.~* Life expectancy ≥ 12 weeks.~* Radiographically measurable per RECIST v1.1.~* Documented FGF/FGFR alteration and have either 1a) failed at least 1 previous treatment for their metastatic or surgically unresectable urothelial carcinoma (ie, chemotherapy, immunotherapy) or 1b) have not received chemotherapy due to poor ECOG status or 2) have insufficient renal function.~Exclusion Criteria:~* Prior receipt of a selective FGFR inhibitor.~* Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug.~* Inability or unwillingness to swallow pemigatinib or significant gastrointestinal disorder(s) that could interfere with the absorption, metabolism, or excretion of pemigatinib.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A-ID (Intermittent Dose) Pemigatinib (Type: EXPERIMENTAL): Pemigatinib in subjects with FGFR3 mutations or fusions.
- Cohort A-CD (Continuous Dose) Pemigatinib (Type: EXPERIMENTAL): Pemigatinib in subjects with FGFR3 mutations or fusions.
- Cohort B Pemigatinib (Type: EXPERIMENTAL): Pemigatinib in subjects with other FGF/FGFR alterations.

Based on this trial design, predict the completion outcome and termination type (if applicable).